Summary
Researchers from the University of Barcelona found that using two drugs, pemafibrate and telmisartan, together may help treat fatty liver disease, also known as MASLD. This condition affects about a quarter of U.S. adults. The study showed that this drug combination could lower fat in the liver and reduce related heart risks in laboratory tests.
Key Facts
- The University of Barcelona conducted the study on fatty liver disease (MASLD).
- MASLD is the most common chronic liver disease in the U.S., impacting about 25% of adults.
- The study tested pemafibrate and telmisartan, which are already used for other health issues.
- Pemafibrate is used in Japan to treat blood fat issues, while telmisartan is a blood pressure medicine used widely, including in the U.S.
- The drugs were tested in animal models and showed a reduction in liver fat.
- The study suggests that these drugs could be used in the early stages of MASLD to prevent progression.
- Lifestyle changes are important for MASLD treatment, but they can be challenging for patients to stick to.
- Early diagnosis and treatment of MASLD can prevent severe complications and lower mortality rates.
